Thallion Pharmaceuticals Inc. (TSX: TLN) is a biotechnology company focused on developing a novel treatment for Shiga Toxin producing E coli infections.

Events and Related News

›› more

News

May 9, 2012

THALLION AND LFB REPORT POSITIVE TOP-LINE RESULTS FROM THE PHASE II SHIGATEC TRIAL AT ‘VTEC 2012’

April 24, 2012

THALLION ANNOUNCES 2012 FIRST QUARTER RESULTS AND PROVIDES SHIGAMABS UPDATE

February 22, 2012

THALLION ANNOUNCES 2011 YEAR END RESULTS

›› archives